Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792991 | 0.84 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL7702540 | 0.82 | DAO (0.55) | DAOPOLBMEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL3925843 | 0.82 | DAO (0.55) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL11691177 | 0.80 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL11431122 | 0.79 | DAO (0.60) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL444120 | 0.78 | DAO (0.58) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL14701887 | 0.76 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL2924922 | 0.76 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL7596452 | 0.76 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL7428616 | 0.76 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6987188-B2 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | DAX SCOTT | 2006-01-17 | — | — | US | disclosed |
| US-20050054709-A1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | DAX SCOTT (US) | 2005-03-10 | — | — | US | disclosed |
| US-6841552-B1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1177172-A1 | 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000068197-A1 | 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054709-A1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | NPY1R, NPY4R, NPY2R | DAO 564/4885POLB 4449/4885MEN1 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.